This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ahmad, S. A. Articles by Pisters, P. W.T. Search for Related Content PubMed PubMed Citation Articles by Ahmad, S. A. Articles by Pisters, P. W.T. Social Bookmarking                            What's this?

Extraosseous Osteosarcoma: Response to Treatment and Long-Term Outcome

From the Multidisciplinary Sarcoma Center and Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

Address reprint requests to Peter W.T. Pisters, MD, Department of Surgical Oncology, Box 444, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009; email: ppisters{at}mdanderson.org

PURPOSE: To evaluate the clinicopathologic features of extraosseous osteosarcoma (EOO), a rare soft tissue form of osteosarcoma, and to examine its response to multimodality therapy.

PATIENTS AND METHODS: The medical records of all patients with EOO evaluated at The University of Texas M.D. Anderson Cancer Center between 1960 and 1999 were reviewed for clinicopathologic factors, treatment, and outcome.

RESULTS: Sixty consecutive patients with EOO were identified, including 38 patients with localized (American Joint Committee on Cancer stages I to III) disease. The majority of patients presented with T2 tumors (n = 35, 58%), and 90% of tumors were located beneath the investing fascia. Twenty-seven patients with measurable and assessable disease were treated with doxorubicin-based chemotherapy (median doxorubicin starting dose, 75 mg/m²; median number of cycles, four). The overall response rate was 19%, with two complete and three partial responses; one (6%) of 18 doxorubicin-treated patients who underwent subsequent surgery had a pathologic complete response. For the subset of 30 patients with localized disease treated at M.D. Anderson, the 5-year actuarial local recurrence–free, distant recurrence–free, event-free, and disease-specific survival rates were 82% (95% confidence interval [CI], 70% to 98%), 64% (95% CI, 43% to 93%), 47% (95% CI, 30% to 70%), and 46% (95% CI, 26% to 80%), respectively.

CONCLUSION: EOO should be considered clinically and therapeutically distinct from osseous osteosarcoma. Radiographic response rates and pathologic complete response rates to doxorubicin-based systemic therapy are low.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Kemmer, C. Grass, S. Siemer, and M. Stoeckle First case of a primary osteosarcoma of the ureter: diagnostic findings, course of disease and treatment QJM, August 1, 2008; 101(8): 663 - 665. [Full Text] [PDF]

				J. Vardy, A.M. Joshua, S.J. Clarke, P.M. Yarrow, and B.P.C. Lin Small Blue Cell Tumors of the Rectum: CASE 1. Ewing's Sarcoma of the Rectum J. Clin. Oncol., February 1, 2005; 23(4): 910 - 912. [Full Text] [PDF]